Cagrilintide/semaglutide
RENEW 4
Novo Nordisk · Phase 3 · Recruiting · Enrollment 285
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Cagrilintide + placebo semaglutide in device 1 and placebo cagrilintide in device 2 | n/r | n/r | n/r | n/r | n/r |
| Cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1 | n/r | n/r | n/r | n/r | n/r |
| Placebo cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1 | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.